ERBB2 and breast carcinoma: Our results on fibroblasts protecting only a subset of breast cancer cell lines from HER2-targeted therapy are supported by a previous study that demonstrated the heterogeneous effects of extracellular ligands in the response of HER2+ breast cancer cells to lapatinib [13].